Clinical Policy: Icosapent ethyl (Vascepa)
Reference Number: HIM.PA.29
Effective Date: 12.01.18
Last Review Date: 02.19
Line of Business: HIM

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Icosapent ethyl (Vascepa®) is an ethyl ester of eicosapentaenoic acid (EPA).

FDA Approved Indication(s)
Vascepa is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

Limitation(s) of use:
- The effect of Vascepa on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
- The effect of Vascepa on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Vascepa is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Hypertriglyceridemia (must meet all):
      1. Diagnosis of hypertriglyceridemia;
      2. Age ≥ 18 years;
      3. Fasting triglycerides ≥ 500 mg/dL (lab must be dated within 90 days);
      4. Failure of a ≥ 3 consecutive month trial of fibrate therapy in the last 6 months at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
      5. Failure of omega-3-acid ethyl esters (generic Lovaza®) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
      6. Dose does not exceed 4 g (4 capsules) per day.

   Approval duration: 6 months

   B. Other diagnoses/indications
      1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace.
II. Continued Therapy

A. Hypertriglyceridemia (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   2. Member is responding positively to therapy as evidenced by:
      a. Initial re-authorization: 20% reduction in TG levels from baseline;
      b. Subsequent re-authorizations: continued reduction or maintenance in reduction of TG levels from baseline;
   3. If request is for a dose increase, new dose does not exceed 4 g (4 capsules) per day.
   Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   Approval duration: Duration of request or 12 months (whichever is less); or
   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – HIM.PHAR.21 for health insurance marketplace or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation Key
EPA: eicosapentaenoic acid
FDA: Food and Drug Administration
TG: triglyceride

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>fenofibrate (TriCor®)</td>
<td>48-145 mg PO QD</td>
<td>145 mg/day</td>
</tr>
<tr>
<td>gemfibrozil (Lopid®)</td>
<td>600 mg PO BID</td>
<td>1,200 mg/day</td>
</tr>
<tr>
<td>omega-3-acid ethyl esters (Lovaza®)</td>
<td>4 g PO QD or 2 g PO BID</td>
<td>4 g/day</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.
Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components
- Boxed warning(s): none reported

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertriglyceridemia</td>
<td>2 g PO BID</td>
<td>4 g/day</td>
</tr>
</tbody>
</table>

VI. Product Availability

Capsules: 0.5 g, 1 g

VII. References


Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Event Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created.</td>
<td>12/16</td>
<td>02/17</td>
</tr>
<tr>
<td>Preferencing for generic Lovaza added in line with clinical guidance per SDC recommendation</td>
<td>06/17</td>
<td></td>
</tr>
<tr>
<td>Retired and added to ST policy</td>
<td>02.18</td>
<td>02.18</td>
</tr>
<tr>
<td>Policy reinstated as this drug requires PA not step therapy</td>
<td>11.08.18</td>
<td>11.08.18</td>
</tr>
<tr>
<td>1Q 2019 annual review: no significant changes; added age limit; references reviewed and updated.</td>
<td>11.20.18</td>
<td>02.19</td>
</tr>
</tbody>
</table>

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and
accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

For Health Insurance Marketplace members, when applicable, this policy applies only when the prescribed agent is on your health plan approved formulary. Request for non-formulary drugs must be reviewed using the non-formulary policy; HIM.PA.103.